慢性心不全における非特異的免疫調節療法の結果 (ACCLAIM試験):プラセボ対照ランダム化試験
Guillermo Torre-Amione1, Stefan D Anker, Robert C Bourge
1Heart Transplant Program, Methodist DeBakey Heart Center, Methodist Hospital, Houston, TX 77030, USA. gtorre@tmhs.org
Lancet (London, England)
|January 22, 2008
まとめ
免疫調節療法 (IMT) は,特定の慢性心不全患者グループにおいて潜在的効果を示した. 前回の心筋梗塞のない患者またはNYHAクラスIIの患者は,IMTで心血管イベントの減少を経験しました.
科学分野:
- 心臓病学 心臓病学
- 免疫学 免疫学とは
- 薬理学 薬理学とは
背景:
- 炎症メディエーターは慢性心不全 (CHF) の発症と進行に関与しています.
- CHF患者のこれらの病理生理学的メカニズムに対する対策として,免疫調節療法 (IMT) を調査した.
研究 の 目的:
- 慢性心不全 (CHF) 患者のデバイスベースの非特異性免疫調節療法 (IMT) の有効性を評価する.
- 左心室シストリック機能不全のCHF患者における全原因死亡率または心血管入院の複合エンドポイントに対するIMTの影響を評価する.
主な方法:
- NYHA機能性II-IVクラスCHFの患者2426人を対象としたダブルブラインド,プラセボ対照試験です.
- 患者はIMTまたはプラセボを指定された間隔でイントラグルテアル注射で投与された.
- 主要エンドポイントは,治療の意図によって分析された,死亡までの時間または最初の心血管疾患の入院でした.
主要な成果:
- 全体として,IMTは10.2ヶ月の平均フォローアップ期間中にプライマリエンドポイント (HR 0.92; p=0.22) を有意に低下させなかった.
- しかし,IMTは特定のサブグループでリスクの有意な減少を示した:前回の心筋梗塞のない患者の26% (p=0.02) とNYHAクラスIIの患者の39% (p=0.0003).
結論:
- 非特異的免疫調節療法 (IMT) は,心不全人口の特定のセグメントに治療上の利点を提供することがあります.
- IMTは,前述の心筋梗塞のないCHF患者およびNYHAクラスIIの患者にとって潜在的な治療法である可能性があります.
関連する概念動画
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...